|
|
||||||||
1 ,5 Department of Infectious Diseases and Immunology, Blackburn Building DO61 and Department of Medicine5 , University of Sydney, Sydney, Australia
2 Institute for Eye Research, Sydney, Australia
3 School of Optometry and Vision Science, The University of New South Wales, Sydney, Australia
4 Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia
6 Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia
7 ,9 Department of Medicine7 and Department of Paediatrics and Child Health9 , University of Queensland, Brisbane, Australia
8 Department of Respiratory Medicine, Royal Children's Hospital, Brisbane, Australia
Correspondence
Colin Harbour
charbour{at}infdis.usyd.edu.au
Received 19 July 2006
Accepted 11 August 2006
Abbreviations: CF, cystic fibrosis; CI, confidence interval; RR, relative risk.
| INTRODUCTION |
|---|
|
|
|---|
Protease IV, a 26 kDa serine endoprotease (O'Callaghan et al., 1996; Engel et al., 1998a), is secreted by most P. aeruginosa isolates causing microbial keratitis and in association with other proteases has a major role in corneal virulence (O'Callaghan et al., 1996; Engel et al., 1997, 1998b; Wilderman et al., 2001). The virulence of protease IV in ocular infection has been attributed to the destruction of host proteins, including fibrinogen and components of the immune system (Engel et al., 1998a). Protease IV also degrades structural proteins such as elastin, facilitating bacterial adhesion and infection. Limited in vitro data suggest that protease IV may contribute to acute lung injury induced by P. aeruginosa through loss of surfactant function (Malloy et al., 2005). There is little information on protease IV secretion by clinical lung isolates.
P. aeruginosa has a unique relationship with the CF lung. Infections in early childhood are often acute and transient, and virulence factors, including the proteases, are expressed at high levels (Jain et al., 2004). However, over time the organism undergoes changes that enable it to persist indefinitely in the face of aggressive antibiotic therapy (Jain et al., 2004). These changes include down-regulation of virulence factors required for acute infection, such as the proteases, and an up-regulation of genes required for biofilm development.
It is widely accepted that most CF patients acquire unique (non-clonal) P. aeruginosa strains from the environment, although clonal P. aeruginosa strains have been reported with increasing frequency in recent years (Jones et al., 2001; McCallum et al., 2001; Scott & Pitt, 2004). Two clonal strains, the Australian epidemic strain (AES)-1 (formerly known as the Melbourne epidemic strain, MES, m16 or PI) and AES-2 (PII) currently infect from 10 to 40 % of patients in six CF clinics in eastern Australia (Armstrong et al., 2003; O'Carroll et al., 2004; H. Service, C. Lee, B. Rose, M. Elkins, P. Bye & C. Harbour, unpublished data). The properties conferring the enhanced colonization of clonal strains have not been defined. The major aim of this study was to examine protease IV production in a series of clonal and non-clonal P. aeruginosa isolates from the chronically infected CF lung.
| METHODS |
|---|
|
|
|---|
Bacteria were grown in tryptone soya broth to late exponential phase (OD600
1.6) at 37 °C with rapid agitation. The wound-derived P. aeruginosa reference strain PAO1 (Holloway et al., 1979) was used as a control. Supernatants were collected and filtered through a 0.22 µm filter to remove any remaining cells. Cell suspensions were used for the detection of the prpL gene.
Western blotting. Western blotting to detect protein was carried out on 21 µl supernatant using standard techniques. Blots were incubated overnight with rabbit polyclonal anti-protease IV antibody (1 : 5000) (kindly donated by Brett Thibodeaux, Department of Microbiology, Immunology and Parasitology, Louisiana State University, Medical Center, New Orleans, LA, USA) and bands then imaged using a calibrated densitometer and QuantityOne software (Bio-Rad). All isolates were examined twice on different occasions.
Gelatin zymography. Gelatin zymography to assess protease IV activity was carried out on 21 µl supernatant using 7.5 % polyacrylamide gels containing 0.1 % (w/v) gelatin (Zhu et al., 2002). Zymograms were imaged using a calibrated densitometer and QuantityOne software (Bio-Rad). All isolates were tested twice on different occasions.
PCR for the protease IV gene. DNA was extracted from cell suspensions using the microLYSIS kit (Microzone). PCR was carried out using combinations of two sets of primers covering different parts of the protease IV gene: those described by Cabellero and colleagues (Caballero et al., 2004) (designated here as CabF and CabR) and the in-house designed primers 5'-TATTTCGCCGACTCCCTGTA-3' (TCF) and 5'-GAATAGACGCCGCTGAAATC-3' (TCR). The CabF/TCR combination yielded a 353 bp product, the TCF/CabR combination a 780 bp product and the TCF/TCR combination a 752 bp product. PCRs were performed in 50 µl mixes containing 25 µl Green GoTaq master mix (Promega), 1.25 µM forward and reverse primers, 2.5 µl 4 % (v/v) glycerol and 2.5 µl template. An annealing temperature of 60 °C was used for each of the PCRs.
Dot hydridization. A DIG-labelled DNA probe was generated from the PAO1 strain using the CabF/TCR primer combination (above) according to the manufacturer's instructions (Roche Diagnostics). Bacterial DNA extractions were dot blotted onto Hybond-N+ membrane (General Electric Healthcare). Blots were then hybridized using DIG EasyHyb buffer (Roche Diagnostics). Following a standard high-stringency wash, hybrids were visualized by standard alkaline phosphatase colorimetric detection (Bio-Rad). Pseudomonas putida cells were used as a negative control.
Statistics. Tests of association between the production and secretion of protease IV and genotype were carried out using the Mantel-Haenszel method and Pearson's chi-square tests. P values <0.05 were considered significant. Relative risk (RR) and 95 % confidence intervals (CIs) were used to determine the strength of the associations.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
|
|
PCR for the prpL gene
PCR was carried out on the ten isolates producing negative results by Western blotting and zymography. Nine of the ten were positive for at least one of the PCR assays confirming that the prpL gene is conserved among CF isolates; seven yielded a product using the CabF/TCR primer combination and two using the TCF/CabR and TCF/TCR combinations. The remaining sample (non-clonal) was negative for all PCRs. All amplicons were of the size predicted from the primer design. The isolate with negative results on all PCRs was also negative by dot hybridization, suggesting that the prpL gene was lost or mutated.
Protease IV expression: non-clonal versus clonal isolates
The expression profile for protease IV in the non-clonal strains was markedly different from that in the clonal strains (Table 1
). Collectively, clonal isolates were 1.6 times more likely to produce protease IV than non-clonal isolates (P=0.007), and were 3 times more likely to have active protein (P<0.001). Sixteen of eighteen (89 %) Western blot-positive clonal isolates had protease activity on the zymogram compared with only five of fourteen (36 %) Western blot-positive non-clonal isolates. All but one of the isolates testing negative by Western blotting and zymography fell into the non-clonal group. Recent studies have indicated that P. aeruginosa adapts to the hostile environment of the CF lung by progressively undergoing phenotypic or genotypic changes that down-regulate virulence factors required for acute infection and up-regulate factors required for biofilm formation (Smith et al., 2006). Our finding that only about half of the non-clonal isolates produced protease IV and less than one quarter secreted the protein suggests that protease IV is among the virulence factors usually down-regulated with chronic infection in the CF lung. Nonetheless, there was considerable strain-to-strain variation in the amount of protease IV protein produced by non-clonal strains, and a few produced higher levels of the protein than seen in any of the clonal isolates or PAO1. It has been reported that the expression of virulence factors is increased on exacerbation of symptoms (Grimwood et al., 1993). However, there was no relationship between protease IV production and the exacerbation of symptoms at the time of collection of the sputum.
Our finding that most isolates of both clonal strains secreted protease IV was of particular interest. The amount of protease IV produced by isolates of clonal strains was relatively uniform between and across the two groups, and in general was slightly less than that of PAO1. There is evidence in support of person-to-person spread of clonal strains, but acquisition from a common source has not been excluded. It is likely that the enhanced infectivity of clonal strains is multifactorial. However, we hypothesize that clonal strains, in contrast to non-clonal strains, have the ability to adapt for long-term survival in the CF lung by resisting modifications to the expression of virulence factors such as protease IV, and that this promotes infectivity and/or facilitates person-to-person spread.
CF lung versus corneal keratitis isolates
Comparisons of data from non-clonal CF isolates with our findings from a study of microbial keratitis (Zhu et al., 2002) showed that the proportion of isolates with active protease IV was much higher among the keratitis group; 82 % (14/17) of microbial keratitis isolates compared with 25 % of non-clonal CF isolates. This discrepancy is likely to reflect both the different anatomical site and the nature of infection (acute in the case of keratitis versus chronic in the case of CF).
In summary, this is the first study of the protease IV protein in a substantial number of P. aeruginosa isolates from the CF lung. This study has shown that the protease IV gene is highly conserved among CF lung isolates, which suggests that protease IV may have an important role in the pathogenesis of P. aeruginosa at this site. However, further studies will be needed to establish the contribution of protease IV to acute lung infection in young CF patients.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Sarnovsky, J. Rea, M. Makowski, R. Hertle, C. Kelly, A. Antignani, D. V. Pastrana, and D. J. FitzGerald Proteolytic Cleavage of a C-terminal Prosequence, Leading to Autoprocessing at the N Terminus, Activates Leucine Aminopeptidase from Pseudomonas aeruginosa J. Biol. Chem., April 10, 2009; 284(15): 10243 - 10253. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bellemare, N. Vernoux, D. Morisset, and Y. Bourbonnais Human Pre-Elafin Inhibits a Pseudomonas aeruginosa-Secreted Peptidase and Prevents Its Proliferation in Complex Media Antimicrob. Agents Chemother., February 1, 2008; 52(2): 483 - 490. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Tingpej, L. Smith, B. Rose, H. Zhu, T. Conibear, K. Al Nassafi, J. Manos, M. Elkins, P. Bye, M. Willcox, et al. Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis J. Clin. Microbiol., June 1, 2007; 45(6): 1697 - 1704. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |